Literature DB >> 1510406

Helicobacter pylori infection in a pediatric population: in vitro susceptibilities to omeprazole and eight antimicrobial agents.

V G Loo1, P Sherman, A G Matlow.   

Abstract

The in vitro activities of omeprazole and eight antimicrobial agents against 18 clinical strains of Helicobacter pylori isolated from a pediatric population were determined by an agar dilution method. Ampicillin and erythromycin were the most active agents in vitro. All strains were susceptible to azithromycin, ciprofloxacin, doxycycline, metronidazole, and tinidazole. One isolate demonstrated resistance to cefixime (MIC, greater than or equal to 4 micrograms/ml). H. pylori was inhibited by the proton pump inhibitor omeprazole.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1510406      PMCID： PMC188850          DOI： 10.1128/AAC.36.5.1133

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime.

Authors:  T U Westblom; S Gudipati; B R Midkiff
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-09       Impact factor: 3.267

2.  Omeprazole, Helicobacter pylori, gastritis, and duodenal ulcer.

Authors:  G Biasco; M Miglioli; L Barbara; R Corinaldesi; G di Febo
Journal:  Lancet       Date:  1989-12-09       Impact factor: 79.321

3.  Omeprazole, campylobacter pylori, and duodenal ulcer.

Authors:  P Mainguet; M Delmée; J C Debongnie
Journal:  Lancet       Date:  1989-08-12       Impact factor: 79.321

4.  Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment.

Authors:  E A Rauws; W Langenberg; H J Houthoff; H C Zanen; G N Tytgat
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

5.  Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents.

Authors:  C A McNulty; J Dent; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

6.  Association of Campylobacter pylori on the gastric mucosa with antral gastritis in children.

Authors:  B Drumm; P Sherman; E Cutz; M Karmali
Journal:  N Engl J Med       Date:  1987-06-18       Impact factor: 91.245

7.  Long-term storage of Campylobacter pylori.

Authors:  B Drumm; P Sherman
Journal:  J Clin Microbiol       Date:  1989-07       Impact factor: 5.948

8.  Interpretative criteria for the agar diffusion susceptibility test with azithromycin.

Authors:  A L Barry; R N Jones
Journal:  J Antimicrob Chemother       Date:  1988-11       Impact factor: 5.790

9.  Intrafamilial clustering of Helicobacter pylori infection.

Authors:  B Drumm; G I Perez-Perez; M J Blaser; P M Sherman
Journal:  N Engl J Med       Date:  1990-02-08       Impact factor: 91.245

10.  Susceptibility of clinical isolates of Campylobacter pylori to 24 antimicrobial and anti-ulcer agents.

Authors:  Y Glupczynski; M Delmee; C Bruck; M Labbe; V Avesani; A Burette
Journal:  Eur J Epidemiol       Date:  1988-06       Impact factor: 8.082
View more
  9 in total

1.  Antibiotic resistance of Helicobacter pylori strains in Japanese children.

Authors:  Seiichi Kato; Shigeru Fujimura; Hirokazu Udagawa; Toshiaki Shimizu; Shunichi Maisawa; Kyoko Ozawa; Kazuie Iinuma
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

Review 2.  Gastroenterology--I: Gastroduodenal disease and Helicobacter pylori.

Authors:  M C Bateson
Journal:  Postgrad Med J       Date:  1994-08       Impact factor: 2.401

Review 3.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

Review 4.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 5.  Indications for treatment of Helicobacter pylori infection: a systematic overview.

Authors:  S J Veldhuyzen van Zanten; P M Sherman
Journal:  CMAJ       Date:  1994-01-15       Impact factor: 8.262

Review 6.  Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.

Authors:  M I Wilde; D McTavish
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

7.  A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori.

Authors:  P Patrick Basu; Krishna Rayapudi; Tommy Pacana; Niraj James Shah; Nithya Krishnaswamy; Molly Flynn
Journal:  Am J Gastroenterol       Date:  2011-10-11       Impact factor: 10.864

8.  Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori.

Authors:  Seung Won Ra; Marc A Sze; Eun Chong Lee; Sheena Tam; Yeni Oh; Nick Fishbane; Gerard J Criner; Prescott G Woodruff; Stephen C Lazarus; Richard Albert; John E Connett; Meilan K Han; Fernando J Martinez; Shawn D Aaron; Robert M Reed; S F Paul Man; Don D Sin
Journal:  Respir Res       Date:  2017-05-30

9.  Helicobacter pylori eradication increases the serum high density lipoprotein cholesterol level in the infected patients with chronic gastritis: A single-center observational study.

Authors:  Naoto Iwai; Takashi Okuda; Kohei Oka; Tasuku Hara; Yutaka Inada; Toshifumi Tsuji; Toshiyuki Komaki; Ken Inoue; Osamu Dohi; Hideyuki Konishi; Yuji Naito; Yoshito Itoh; Keizo Kagawa
Journal:  PLoS One       Date:  2019-08-16       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.